Noven To Hold Annual Shareholders’ Meeting On May 14

Public Invited to Listen to Webcast of Meeting

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, will hold its Annual Meeting of Shareholders’ on May 14, 2003, at 10:00 a.m. at Noven corporate headquarters, 11960 SW 144th Street, Miami, Florida. Live audio of the meeting will be available at www.noven.com, and a rebroadcast will be available at the same site. Please visit the site at least 15 minutes in advance to download any required software.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women’s health products company called Novogyne Pharmaceuticals. Noven’s existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot®, licensed to Novogyne, and Estradot®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch®, licensed to Novogyne, and Estalis®, licensed to Novartis Pharma AG). With a range of additional products in development, Noven is committed to becoming the world’s premier transdermal drug delivery company. For additional information, visit Noven’s website at www.noven.com.

Contact:
Investor & Media Contact

Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916